Health condition
Theranostics (lutetium) access
Theranostics pairs a diagnostic scan with a matched radioactive treatment - lutetium-177 therapies for neuroendocrine tumours and advanced prostate cancer being the leading examples; access in the UK runs through specialist nuclear medicine centres.
Why trust this guide
- 01
Editorial team
Written by our editorial team from the UK sources listed on each page.
- 02
Sourced from guidance
Checked against current NHS and UK specialist society guidance at the time of review.
- 03
Current for 2026
Reviewed on 2026-09-27 with the next review scheduled for 2027-09-27.
Key facts
The essentials at a glance.
The symptoms to recognise, when to seek help, which specialist to see, and what treatment usually involves.
-
The scan proves the target is present; the same molecule then delivers radiation to it
-
Lutetium dotatate treats somatostatin-receptor-positive neuroendocrine tumours
-
Lutetium PSMA therapy treats PSMA-avid metastatic prostate cancer after prior treatments
-
Delivery requires licensed nuclear medicine facilities, concentrating provision in specialist centres
Understanding the condition
What it is and what happens next.
What causes it, how it is diagnosed, and the treatment routes available in the UK.
What it is and how it feels
The elegance of theranostics is its honesty: a gallium or fluorine PET scan first shows whether tumour cells display the target - somatostatin receptors in neuroendocrine tumours, PSMA in prostate cancer - and only image-positive patients proceed, swapping the diagnostic isotope for beta-emitting lutetium-177 that irradiates each deposit from within. Treatment is outpatient-based in cycles, generally well tolerated, with kidney and marrow function monitored between doses.
Diagnosis and treatment routes
Trial evidence underpins both flagships - lutetium dotatate delaying progression in midgut NETs, lutetium PSMA extending survival in heavily pre-treated prostate cancer - and UK availability has followed through NICE and specialist commissioning, though geography and capacity still shape waiting times. The route in is referral from your oncology team to a centre delivering molecular radiotherapy, with the qualifying PET scan as the pivotal first step; private provision exists and can shorten the interval to that assessment. If you are waiting for results or want a second opinion on a proposed plan, a private consultation with a specialist who treats this condition regularly can usually be arranged quickly, and most will review your existing scans, biopsy reports and MDT correspondence.
Seeing a specialist
Who to see, and how quickly you can be seen.
The specialist for this condition is usually a consultant oncologist. Your GP can refer you on the NHS, or you can arrange a private consultation directly.
A quiet reminder
This guide is for information, not medical advice.
Your GP knows your history and can tell you which parts apply to you. If in doubt, see them - and seek urgent care for any of the emergency symptoms described above.
Frequently asked
Common questions about Theranostics (lutetium) access.
Quick, plain-English answers to what people ask us most.
-
Can you explain what theranostics (lutetium) access is?
Theranostics (lutetium) access is a medical condition that can affect people differently depending on severity, underlying cause and overall health. A clinician can confirm the diagnosis and explain what it means specifically for you.
-
What causes theranostics (lutetium) access?
Causes vary and can include genetic, environmental, lifestyle and other health-related factors, and in some people no single clear cause is found. Your clinician can help identify anything relevant to your own case.
-
What does theranostics (lutetium) access look like or feel like?
Symptoms vary between individuals and depend on which body systems are affected and how significant the underlying problem is. Keeping track of what you notice, and when, helps your clinician assess it accurately.
-
How worried should I be about theranostics (lutetium) access?
Severity varies from mild and self-limiting to more significant, depending on the underlying cause and how it's managed. A clinical assessment is the best way to understand what it means in your specific situation.
-
Is theranostics (lutetium) access hereditary or genetic?
This depends on the specific condition — some cases have a genetic or familial component, while others are linked more to environmental, lifestyle or other health factors. If you have a relevant family history, it's worth mentioning to your clinician.
-
Is there a cure for theranostics (lutetium) access?
Many cases can be effectively treated or managed, and prevention strategies exist for some causes, though this depends on the specific underlying reason in your case. Your clinician can explain what's realistic for you.
-
How is theranostics (lutetium) access treated?
Treatment is tailored to the underlying cause and severity, and can range from simple lifestyle or self-management measures to medical or specialist intervention.
-
What is the long-term outlook for theranostics (lutetium) access?
This varies depending on the underlying cause, how early it's identified, and how well it responds to treatment — your clinician can give a more specific expectation once assessed.
-
When should specialist referral be considered for theranostics (lutetium) access?
Specialist referral is worth considering if symptoms persist, are getting worse, or aren't responding to initial treatment — your GP can help decide the right pathway and urgency.
-
When should I see a doctor about theranostics (lutetium) access, and how quickly can I be seen privately?
See a doctor if symptoms are persistent, worsening, or affecting your daily life — earlier assessment generally leads to better management. NHS routine referrals for this kind of concern often take 20–45 weeks or longer depending on the area, while a private consultant can typically see you within about 2 weeks, with faster access to scans and specialist opinion.